INTELLIA THERAPEUTICS

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 فبراير 2025 15:01:00 بحسب Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

22 يناير 2025 06:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

16 يناير 2025 09:00:04 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

14 يناير 2025 14:48:02 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

13 يناير 2025 08:46:31 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 يناير 2025 08:45:07 بحسب NetDania Notify

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

09 يناير 2025 15:00:00 بحسب Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 يناير 2025 06:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

31 ديسمبر 2024 09:00:10 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

30 ديسمبر 2024 08:52:39 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

26 ديسمبر 2024 08:45:05 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

19 ديسمبر 2024 08:59:11 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 ديسمبر 2024 13:25:27 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

13 ديسمبر 2024 09:50:31 بحسب NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 ديسمبر 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

25 نوفمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

20 نوفمبر 2024 08:51:21 بحسب NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 نوفمبر 2024 09:10:43 بحسب NetDania Notify

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

16 نوفمبر 2024 09:16:00 بحسب Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07 نوفمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire